)
China Resources Boya Bio-pharmaceutical Group (300294) investor relations material
China Resources Boya Bio-pharmaceutical Group Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Revenue for Q1 2026 was ¥321.13 million, down 40.07% year-over-year due to intensified industry procurement and market competition, leading to declines in both sales volume and prices of core products.
Net profit attributable to shareholders was ¥30.22 million, a decrease of 78.33% year-over-year.
Cash flow from operating activities was negative at ¥127.23 million, down 202.07% year-over-year, mainly due to lower collections.
Financial highlights
Operating income: ¥321.13 million, down 40.07% year-over-year.
Net profit attributable to shareholders: ¥30.22 million, down 78.33% year-over-year.
Net profit excluding non-recurring items: ¥20.32 million, down 80.13% year-over-year.
Basic and diluted EPS: ¥0.06, down 78.57% year-over-year.
Total assets at period end: ¥8.41 billion, down 2.55% from year-end 2025.
Outlook and guidance
Industry-wide procurement and increased competition are expected to continue impacting sales and pricing of core products.
- Revenue up, profit down sharply; divestment and smart factory support core blood business.300294
H2 202521 Mar 2026 - Revenue up, profit down YTD, cash flow pressured, Boya Xinhe deconsolidated.300294
Q3 202522 Dec 2025 - Revenue up 12.5% but net profit down 28.7% amid margin and policy pressures.300294
H1 202522 Dec 2025 - Revenue up 19.49% but net profit down 8.25% as costs rise and cash flow turns negative.300294
Q1 202522 Dec 2025 - Net profit jumped 67% to ¥397M as core blood products outperformed despite revenue decline.300294
H2 202422 Dec 2025 - Revenue and profit fell on divestitures, but blood products and plasma supply expanded.300294
Q3 202422 Dec 2025 - Revenue up 4.7% to RMB128.60b; net profit up 10.2%; major plasma acquisition, dividend declared.300294
H1 202422 Dec 2025
Next China Resources Boya Bio-pharmaceutical Group earnings date
Next China Resources Boya Bio-pharmaceutical Group earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)